Skip to main content

PLEASE NOTE: For everyone’s safety, Fasken recommends anyone on-site at our Canadian offices be familiar with the COVID-19 recommendations in place which may include one or more of the following: social distancing, hand sanitizing, wearing a mask in common areas and proof of full vaccination. These measures apply to lawyers, staff, clients, service providers and other visitors.

Client Work

Transition Therapeutics completes US$25 million private placement

Reading Time 1 minute read Subscribe



Great Point Partners

On November 8, 2006, Transition Therapeutics Inc., a biopharmaceutical company developing novel therapeutics for disease indications with large markets, announced the closing of its previously disclosed private placement financing. It issued 26,881,720 common shares at a price of $0.93 per common share, raising gross proceeds of $25 million from two funds managed by Great Point Partners, LLC. The proceeds from the offering will be used to fund Transition's clinical studies, research and product development, working capital and general corporate purposes. Stephen Erlichman and John Sabetti of Fasken Martineau acted as Canadian legal advisors to Great Point Partners in this transaction.



    Receive email updates from our team